Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Graham DY and Gisbert JP |
Letter: clarithromycin dose for H. pylori therapy remains unresolved. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238583
|
Wheeldon TU et al. |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15191514
|
Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Romero-Gómez M et al. |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616169
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Perri F et al. |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421878
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421879
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Cardenas VM et al. |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16393310
|
Kamada T et al. |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12869086
|
Murakami K et al. |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12492740
|
Lamouliatte H et al. |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535872
|
Miehlke S et al. |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535873
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Lai KC et al. |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535877
|
Gisbert JP et al. |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10540045
|
Bruley Des Varannes S et al. |
There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472320
|
Adachi K et al. |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472321
|
Gschwantler M et al. |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468682
|
Lane JA et al. |
Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21366634
|
Molina-Infante J et al. |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:25776067
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Chan FK et al. |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632651
|
Khurana R et al. |
Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17305754
|
Pipkin GA et al. |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768524
|
Louw JA et al. |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768531
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Sung JJ et al. |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726384
|
Wong WM et al. |
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929398
|
Pazzi P et al. |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726385
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Talley NJ et al. |
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678811
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Ricciardiello L et al. |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678812
|
Cammarota G et al. |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678813
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Di Caro S et al. |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876707
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Wu JC et al. |
Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876709
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Elizalde JI et al. |
Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876713
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
Savarino V et al. |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:9892878
|
Furuta T et al. |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17697203
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Goh KL et al. |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663838
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Kolkman JJ et al. |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663840
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Laurent J et al. |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11683693
|
Kashimura H et al. |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215732
|
Lee JM et al. |
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215733
|
Kim YS et al. |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21923713
|
You JH et al. |
Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421876
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Vakil N et al. |
Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803603
|
Cammarota G et al. |
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15043520
|
Thung I et al. |
Review article: the global emergence of Helicobacter pylori antibiotic resistance. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26694080
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Graham DY et al. |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102946
|
Zanten SJ et al. |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102960
|
Pilotto A and Malfertheiner P |
Review article: an approach to Helicobacter pylori infection in the elderly. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929385
|
Van der Wouden EJ et al. |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102961
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Rinaldi V et al. |
The management of failed dual or triple therapy for Helicobacter pylori eradication. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354202
|
Breuer T et al. |
Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354204
|
Osato MS et al. |
Comparative efficacy of new investigational agents against Helicobacter pylori. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11284777
|
Xiao SD et al. |
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11136281
|
Wong WM et al. |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16423001
|
Jung YS et al. |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28497487
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Lim AG et al. |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218079
|
Nista EC et al. |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569121
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|
Harris AW et al. |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971302
|
Mégraud F and Lamouliatte H |
Review article: the treatment of refractory Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786627
|
Moshkowitz M et al. |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971304
|
Savarino V et al. |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886045
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Laine L et al. |
Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971306
|
Chen PY et al. |
Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074519
|
Zamani M et al. |
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074507
|